Vertex pays second-highest M&A premium as sole bidder for Crinetics

Vertex Pharmaceuticals emerged as the only bidder for Crinetics Pharmaceuticals, aiming to acquire the company.

The bid involved a premium that ranks as the second-highest in the biopharma sector for the current year, reflecting a strong valuation.

The transaction underscores Vertex's strategy to expand its pipeline, while the lack of competing offers suggests limited interest from other potential buyers.